DOR to loncastuximab tesirine, PFS, and OS. DOR by B-NHL subtype (A), for patients with DLBCL by dose (B), and for patients with DLBCL by response (C). (D) PFS for all patients with B-NHL and those with DLBCL, MCL, and FL. (E) OS for all patients with B-NHL and those with DLBCL, MCL, and FL.